{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:55:02Z","timestamp":1794048902442,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Youcare Pharmaceutical Group Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66876-5","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T04:23:49Z","timestamp":1764563029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-1397","authenticated-orcid":false,"given":"Ze-Ao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Shen","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9131-6053","authenticated-orcid":false,"given":"Zhi-Kang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3556-7459","authenticated-orcid":false,"given":"Geng-Shen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"66876_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"Y-C Hsu","year":"2023","unstructured":"Hsu, Y.-C., Huang, D. Q. & Nguyen, M. H. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. 20, 524\u2013537 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"66876_CR2","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","volume":"380","author":"DL Thomas","year":"2019","unstructured":"Thomas, D. L. & Longo, D. L. Global elimination of chronic hepatitis. N. Engl. J. Med. 380, 2041\u20132050 (2019).","journal-title":"N. Engl. J. Med."},{"key":"66876_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(16)31018-2","volume":"388","author":"SZ Wiktor","year":"2016","unstructured":"Wiktor, S. Z. & Hutin, Y. J. F. The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts. Lancet 388, 1030\u20131031 (2016).","journal-title":"Lancet"},{"key":"66876_CR4","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","volume":"64","author":"S Tong","year":"2016","unstructured":"Tong, S. & Revill, P. Overview of hepatitis B viral replication and genetic variability. J. Hepatol. 64, S4\u2013S16 (2016).","journal-title":"J. Hepatol."},{"key":"66876_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","volume":"26","author":"K-N Tsai","year":"2018","unstructured":"Tsai, K.-N., Kuo, C.-F. & Ou, J.-H. J. Mechanisms of hepatitis B virus persistence. Trends Microbiol. 26, 33\u201342 (2018).","journal-title":"Trends Microbiol."},{"key":"66876_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra2211764","volume":"388","author":"G Dusheiko","year":"2023","unstructured":"Dusheiko, G., Longo, D. L., Agarwal, K. & Maini, M. K. New approaches to chronic hepatitis B. N. Engl. J. Med. 388, 55\u201369 (2023).","journal-title":"N. Engl. J. Med."},{"key":"66876_CR7","doi-asserted-by":"crossref","unstructured":"Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl. Med. 9, eaan0241 (2017).","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"66876_CR8","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1053\/j.gastro.2018.03.021","volume":"154","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients. Gastroenterology 154, 2222\u20132236 (2018).","journal-title":"Gastroenterology"},{"key":"66876_CR9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41590-024-01928-4","volume":"25","author":"K Heim","year":"2024","unstructured":"Heim, K. et al. Attenuated effector T cells are linked to control of chronic HBV infection. Nat. Immunol. 25, 1650\u20131662 (2024).","journal-title":"Nat. Immunol."},{"key":"66876_CR10","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1172\/JCI121960","volume":"128","author":"AR Burton","year":"2018","unstructured":"Burton, A. R. et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J. Clin. Investig. 128, 4588\u20134603 (2018).","journal-title":"J. Clin. Investig."},{"key":"66876_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","volume":"3","author":"MK Maini","year":"2018","unstructured":"Maini, M. K. & Pallett, L. J. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. Lancet Gastroenterol. Hepatol. 3, 192\u2013202 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"66876_CR12","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.3350\/cmh.2024.0780","volume":"31","author":"D Wu","year":"2025","unstructured":"Wu, D. et al. Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0. Clin. Mol. Hepatol. 31, S134\u2013S164 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"66876_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/v14040657","volume":"14","author":"M Moini","year":"2022","unstructured":"Moini, M. & Fung, S. HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure. Viruses 14, 657 (2022).","journal-title":"Viruses"},{"key":"66876_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/ID9.0000000000000128","volume":"4","author":"Organization, W. H","year":"2024","unstructured":"Organization, W. H Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (text extract): executive summary. Infect. Dis. Immun. 4, 103\u2013105 (2024).","journal-title":"Infect. Dis. Immun."},{"key":"66876_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jvh.14032","volume":"31","author":"GLH Wong","year":"2024","unstructured":"Wong, G. L. H. Updated guidelines for the prevention and management of chronic hepatitis B\u2014World Health Organization 2024 compared with China 2022 HBV guidelines. J. Viral Hepat. 31, 13\u201322 (2024).","journal-title":"J. Viral Hepat."},{"key":"66876_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/HEP.0000000000000524","volume":"79","author":"P Jiang","year":"2024","unstructured":"Jiang, P. et al. Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-\u03b1 in patients with chronic hepatitis B. Hepatology 79, 167\u2013182 (2024).","journal-title":"Hepatology"},{"key":"66876_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11901-010-0055-1","volume":"9","author":"V Rijckborst","year":"2010","unstructured":"Rijckborst, V. & Janssen, H. L. The role of interferon in hepatitis B therapy. Curr. Hepat. Rep. 9, 231\u2013238 (2010).","journal-title":"Curr. Hepat. Rep."},{"key":"66876_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12072-023-10597-8","volume":"18","author":"F-S Wang","year":"2023","unstructured":"Wang, F.-S., Li, J. & Zhang, C. Why is the functional cure rate of young children with chronic hepatitis B receiving antiviral therapy considerably high?. Hepatol. Int. 18, 296\u2013298 (2023).","journal-title":"Hepatol. Int."},{"key":"66876_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09723-0","volume":"24","author":"QL Zeng","year":"2024","unstructured":"Zeng, Q. L. et al. Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study. BMC Infect. Dis. 24, 830 (2024).","journal-title":"BMC Infect. Dis."},{"key":"66876_CR20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","volume":"9","author":"M-F Yuen","year":"2024","unstructured":"Yuen, M.-F. et al. VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. Lancet Gastroenterol. Hepatol. 9, 1121\u20131132 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"66876_CR21","doi-asserted-by":"publisher","first-page":"S809","DOI":"10.1016\/S0168-8278(24)02236-0","volume":"80","author":"MF Yuen","year":"2024","unstructured":"Yuen, M. F. et al. Imdusiran (AB\u2212729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment. J. Hepatol. 80, S809\u2013S810 (2024).","journal-title":"J. Hepatol."},{"key":"66876_CR22","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S0168-8278(24)00471-9","volume":"80","author":"JL Hou","year":"2024","unstructured":"Hou, J. L. et al. Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (Piranga). J. Hepatol. 80, S26 (2024).","journal-title":"J. Hepatol."},{"key":"66876_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","volume":"81","author":"K Agarwal","year":"2024","unstructured":"Agarwal, K. et al. JNJ\u221273763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. J. Hepatol. 81, 404\u2013414 (2024).","journal-title":"J. Hepatol."},{"key":"66876_CR24","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen, M. F. et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N. Engl. J. Med. 387, 1957\u20131968 (2022).","journal-title":"N. Engl. J. Med."},{"key":"66876_CR25","doi-asserted-by":"publisher","first-page":"102542","DOI":"10.1016\/j.omtn.2025.102542","volume":"36","author":"ZA Huang","year":"2025","unstructured":"Huang, Z. A. et al. Design, pharmacology, and toxicology of a novel chemically modified siRNA targeting hepatic angiotensinogen. Mol. Ther. Nucleic Acids 36, 102542 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"66876_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1073\/pnas.84.4.1005","volume":"84","author":"MA Sells","year":"1987","unstructured":"Sells, M. A., Chen, M. L. & Acs, G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84, 1005\u20131009 (1987).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66876_CR27","doi-asserted-by":"crossref","unstructured":"Hayer, J. et al. HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Res. 41, D566\u2013D570 (2013).","DOI":"10.1093\/nar\/gks1022"},{"key":"66876_CR28","doi-asserted-by":"crossref","unstructured":"Velkov, S., Ott, J. J., Protzer, U. & Michler, T. The global hepatitis B virus genotype distribution approximated from available genotyping data. Genes 9, 495 (2018).","DOI":"10.3390\/genes9100495"},{"key":"66876_CR29","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1261\/rna.25706","volume":"12","author":"AL Jackson","year":"2006","unstructured":"Jackson, A. L. et al. Widespread siRNA \u201coff-target\u201d transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179\u20131187 (2006).","journal-title":"RNA"},{"key":"66876_CR30","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1093\/nar\/gki762","volume":"33","author":"X Lin","year":"2005","unstructured":"Lin, X. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33, 4527\u20134535 (2005).","journal-title":"Nucleic Acids Res."},{"key":"66876_CR31","doi-asserted-by":"publisher","first-page":"10754","DOI":"10.1093\/nar\/gkae741","volume":"52","author":"K Nomura","year":"2024","unstructured":"Nomura, K. et al. Synthesis of 2\u2032-formamidonucleoside phosphoramidites for suppressing the seed-based off-target effects of siRNAs. Nucleic Acids Res. 52, 10754\u201310774 (2024).","journal-title":"Nucleic Acids Res."},{"key":"66876_CR32","doi-asserted-by":"publisher","first-page":"17862","DOI":"10.1073\/pnas.0608578103","volume":"103","author":"LR Huang","year":"2006","unstructured":"Huang, L. R., Wu, H. L., Chen, P. J. & Chen, D. S. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 103, 17862\u201317867 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66876_CR33","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1128\/jvi.69.10.6158-6169.1995","volume":"69","author":"LG Guidotti","year":"1995","unstructured":"Guidotti, L. G., Matzke, B., Schaller, H. & Chisari, F. V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69, 6158\u20136169 (1995).","journal-title":"J. Virol."},{"key":"66876_CR34","unstructured":"Ji, Y. et al. The impact of hepatitis B surface antigen reduction via small interfering RNA treatment on natural and vaccine (BRII-179)-induced hepatitis B vaccine-specific humoral and cellular immune responses. Gastroenterology S0016-5085(25)00466-4 (2025)."},{"key":"66876_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molcel.2021.11.026","volume":"82","author":"HO Iwakawa","year":"2022","unstructured":"Iwakawa, H. O. & Tomari, Y. Life of RISC: formation, action, and degradation of RNA-induced silencing complex. Mol. Cell 82, 30\u201343 (2022).","journal-title":"Mol. Cell"},{"key":"66876_CR36","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong, G. L. H., Gane, E. & Lok, A. S. F. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?. J. Hepatol. 76, 1249\u20131262 (2022).","journal-title":"J. Hepatol."},{"key":"66876_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/vaccines12030237","volume":"12","author":"DD Pooter","year":"2024","unstructured":"Pooter, D. D. et al. mRNA therapeutic vaccine for hepatitis B demonstrates immunogenicity and efficacy in the AAV-HBV mouse model. Vaccines (Basel) 12, 237 (2024).","journal-title":"Vaccines (Basel)"},{"key":"66876_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jhep.2022.12.013","volume":"78","author":"JP Su","year":"2023","unstructured":"Su, J. P. et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models. J. Hepatol. 78, 717\u2013730 (2023).","journal-title":"J. Hepatol."},{"key":"66876_CR39","doi-asserted-by":"crossref","unstructured":"Ganchua, S. C. et al. Reduction of Hepatitis B Surface Antigen Mediated by RNA Interference Therapeutic AB-729 in Chronic Hepatitis B Patients is Associated with T Cell Activation and a Decline in Exhausted CD8 T Cells SAT397 (European Association for the Study of the Liver, 2022).","DOI":"10.1016\/S0168-8278(22)01999-7"},{"key":"66876_CR40","doi-asserted-by":"crossref","unstructured":"Mak, L. Y. et al. Mitigation of Immune Dysfunction in Patients with Sustained Suppression of Hepatitis B Surface Antigen after siRNA Treatment OS-071 (European Association for the Study of the Liver, 2025).","DOI":"10.1016\/S0168-8278(25)00386-1"},{"key":"66876_CR41","unstructured":"Jennifer, S. et al. Proteomic Profiling in Prefilled Syringe Study Demonstrates Bepirovirsen\u2019s Immune Stimulatory Effect Abstract 1139 (American Association for the Study of Liver Diseases, 2025)."},{"key":"66876_CR42","unstructured":"Andre, B. et al. Intrahepatic and Peripheral Immunophenotyping of Participants with Chronic Hepatitis B Receiving Bepirovirsen in the B-fine Study Strongly Suggests that Bepirovirsen may Trigger a Humoral Response Abstract 1215 (American Association for the Study of Liver Diseases, 2025)."},{"key":"66876_CR43","unstructured":"Wen, X. et al. Robust and Sustained Hepatitis B Surface Antigen Reduction after HT-101 Dosed Twice in Chronic Hepatitis B Patients: Results from a Phase \u2160 Study Including Extension Follow-up Data PP0256 (Asia Pacific Association for the Study of the Liver, 2025)."},{"key":"66876_CR44","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1021\/acsomega.4c06840","volume":"10","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. Inhibition of hepatitis B virus replication by a novel GalNAc-siRNA in vivo and in vitro. ACS Omega 10, 484\u2013497 (2025).","journal-title":"ACS Omega"},{"key":"66876_CR45","doi-asserted-by":"publisher","first-page":"104898","DOI":"10.1016\/j.antiviral.2020.104898","volume":"182","author":"BJ Burwitz","year":"2020","unstructured":"Burwitz, B. J., Zhou, Z. & Li, W. Animal models for the study of human hepatitis B and D virus infection: new insights and progress. Antivir. Res. 182, 104898 (2020).","journal-title":"Antivir. Res."},{"key":"66876_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01953-y","volume":"8","author":"BJ Burwitz","year":"2017","unstructured":"Burwitz, B. J. et al. Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques. Nat. Commun. 8, 2146 (2017).","journal-title":"Nat. Commun."},{"key":"66876_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30593-0","volume":"13","author":"S Biswas","year":"2022","unstructured":"Biswas, S. et al. Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity. Nat. Commun. 13, 2995 (2022).","journal-title":"Nat. Commun."},{"key":"66876_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nprot.2015.017","volume":"10","author":"I Mederacke","year":"2015","unstructured":"Mederacke, I., Dapito, D. H., Aff\u00f2, S., Uchinami, H. & Schwabe, R. F. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat. Protoc. 10, 305\u2013315 (2015).","journal-title":"Nat. Protoc."},{"key":"66876_CR49","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41423-022-00939-1","volume":"19","author":"HJ Zhao","year":"2022","unstructured":"Zhao, H. J. et al. Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction. Cell Mol. Immunol. 19, 1347\u20131360 (2022).","journal-title":"Cell Mol. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66876-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66876-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66876-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:29:14Z","timestamp":1767796154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66876-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["66876"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66876-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}